Saturday 17 October 2026 Export PGEN’s income statement to Excel — free account

Precigen, Inc.

Precigen, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $9.7 million, up 146.7% from fiscal 2024. In the quarter to June 2026, revenue grew 6,322.7%, EPS grew 166.7% and free cash flow grew 8.73%, each against the same quarter a year earlier. Insiders bought in the last twelve months.

6.35 0.85 −11.81%

Follow PGEN

Alert me

Market cap: $2.6B
P/E: 0.0×
Fwd P/E: −124×
Dividend yield: —
F-score: 3/9
Altman Z: −16.93
Beneish M: −7.67
Dividend safety: n/a

Overview Business Profile Financial Analysis Income Statement Balance Sheet Cash Flow Metrics & Ratios 10-Q 10-K

Insider Decisions trades per month

Total buys 0.02

Total sells 44.79

Totals in millions of $.

	Dec 25			Mar 26			Jun 26			Sep 26
Buy	—	—	—	—	—	—	—	—	—	1	—	—
Sell	1	2	—	—	1	—	5	3	1	5	—	—

Insider Ownership 53.98%

Capital & Financial Ratios $m

Market Cap 2,580.00

Revenue 85.72

Net Income (157.70)

Free Cash Flow (115.22)

Net Debt 55.67

Current Ratio 4.58

Debt/Equity 2.15

P/E ratio 0.00

Fwd P/E (124.00)

P/S ratio 26.44

P/B ratio 52.01

Past 5Y EPS Growth —

This Y EPS Growth 112.51%

Next Y EPS Growth 270.84%

Next Y revenue growth 2,365.92%

Next 5Y EPS Growth 2.40%

Green and red mark values outside typical ranges. How we judge →

Valuation vs history

EV/Sales, ten years

P/S against its own 10 years 58.26%

10-year low 10-year high

P/B against its own 10 years 93.70%

10-year low 10-year high

EV/Sales against its own 10 years 58.38%

10-year low 10-year high

Dividends

Payout Ratio —

Annual Dividend Rate —

Annual Dividend Yield —

	total	individual payouts
2023	Powerpack
2022	Powerpack
2021	Powerpack
2020	Powerpack
2019	Powerpack

special payouts not included in total or ratios

Assets vs Liabilities $m

	2023	2024	2025	Q'26
Cash	63	98	98	38
Receivables	2	1	4	72
Inventory	—	—	10	20
Other	—	—	—	—
	69	102	115	134

	2023	2024	2025	Q'26
Payables	2	4	12	5
ST’ Debt	—	—	—	—
Other	5	3	2	—
	23	22	37	29

Compound Annual Growth %

	10y	5y	3y
Sales	(25.07%)	(21.26%)	(28.87%)
Cash Flow	0.00%	0.00%	0.00%
Earnings	0.00%	0.00%	0.00%
Book Value	(29.66%)	(20.82%)	(45.08%)

Revenue $m

	Mar	Jun	Sep	Dec	Year
’26	23	55	—	—	—
’25	1	1	3	5	10
’24	1	1	1	1	4
’23	2	2	1	1	6
’22	6	3	17	2	27
’21	25	4	3	(17)	14
’20	30	30	24	(52)	32

Fiscal quarters ending in the months shown.

Operating Cash Flow $m

	Mar	Jun	Sep	Dec	Year
’26	(44)	(18)	—	—	—
’25	(16)	(19)	(29)	(23)	(88)
’24	(14)	(23)	(23)	(8)	(68)
’23	(18)	(16)	(17)	(16)	(67)
’22	(19)	(7)	(24)	(15)	(65)
’21	(16)	(8)	(17)	(15)	(56)
’20	(28)	(14)	(19)	(16)	(77)

Fiscal quarters ending in the months shown.

Free Cash Flow $m

	Mar	Jun	Sep	Dec	Year
’26	(44)	(18)	—	—	—
’25	(17)	(20)	(29)	(23)	(90)
’24	(18)	(25)	(24)	(9)	(77)
’23	(19)	(16)	(17)	(17)	(68)
’22	(20)	(8)	(25)	(15)	(69)
’21	(15)	(9)	(19)	(17)	(60)
’20	(30)	(15)	(20)	(13)	(78)

Fiscal quarters ending in the months shown.

EPS $

	Mar	Jun	Sep	Dec	Year
’26	(0.02)	0.05	—	—	—
’25	(0.18)	(0.09)	(1.06)	(0.01)	(1.37)
’24	(0.10)	(0.23)	(0.09)	(0.06)	(0.47)
’23	(0.10)	(0.08)	(0.08)	(0.13)	(0.39)
’22	(0.10)	(0.09)	0.44	(0.11)	0.14
’21	(0.09)	(0.10)	(0.15)	(0.13)	(0.47)
’20	(0.35)	(0.26)	(0.18)	(0.23)	(1.02)

Fiscal quarters ending in the months shown.

Group	Line	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025	2026e
Price, $
Price, $	Low	18.35	10.26	6.21	3.95	1.26	3.42	1.12	0.81	0.65	1.03	Analyst estimates 2026–2028 Powerpack
	High	39.88	26.99	20.16	9.10	10.87	11.10	3.99	2.29	1.93	5.23
People
People	Employees	935	1,006	979	857	194	191	33	202	143	160
	Revenue/emp, $m	0.20	0.22	0.15	0.11	0.16	0.07	0.82	0.03	0.03	0.06
Income, $m
Income, $m	Revenue	191	219	151	91	32	14	27	6	4	10
	Gross margin, %	67.72	71.89	58.54	32.32	83.20	59.73	76.44	1.70	(8.71)	50.20
	EBT	(194)	(78)	(396)	(171)	(105)	(111)	(80)	(96)	(128)	(251)
	EBT margin, %	(101.69)	(35.71)	(261.88)	(188.78)	(326.72)	(777.79)	(297.17)	(1,547.98)	(3,261.86)	(2,588.18)
	Net income	(190)	(127)	(515)	(324)	(171)	(92)	28	(96)	(126)	(251)
	Depreciation	85	29	67	113	37	27	13	15	11	5
Per share, $
Per share, $	Revenue	1.62	1.83	1.17	0.59	0.19	0.07	0.13	0.03	0.01	0.03
	Earnings	(1.58)	(0.98)	(3.93)	(2.09)	(1.02)	(0.47)	0.14	(0.39)	(0.47)	(1.37)
	Cash flow	(0.42)	(0.86)	(0.96)	(0.88)	(0.46)	(0.28)	(0.32)	(0.27)	(0.25)	(0.28)
	Capex	(0.27)	(0.38)	(0.30)	(0.24)	(0.01)	(0.02)	(0.02)	(0.01)	(0.03)	(0.01)
	Free cash flow	(0.68)	(1.24)	(1.26)	(1.12)	(0.47)	(0.30)	(0.35)	(0.28)	(0.29)	(0.29)
	Book value	4.82	4.55	2.92	0.47	0.40	0.54	0.63	0.48	0.25	0.07
	Shares, m	118	120	130	154	167	198	200	245	268	313
Valuation, ×
Valuation, ×	P/E	0.00	0.00	0.00	0.00	0.00	0.00	10.55	0.00	0.00	0.00
	P/S	15.20	7.37	5.60	9.31	53.27	51.43	11.02	55.39	76.40	135.09
	P/B	5.10	2.96	2.24	11.78	25.37	6.83	2.35	2.91	7.79	62.56
	EV/Sales	13.96	7.03	5.53	10.89	55.51	56.42	9.20	48.51	56.55	136.04
	EV/FCF	(33.17)	(10.37)	(5.11)	(5.70)	(22.75)	(13.41)	(3.57)	(4.42)	(2.89)	(14.67)
Cash, $m
Cash, $m	Operating cash flow	(49)	(104)	(124)	(136)	(77)	(56)	(65)	(67)	(68)	(88)
	Capex	(31)	(45)	(39)	(37)	(1)	(4)	(4)	(1)	(9)	(2)
	Free cash flow	(80)	(149)	(164)	(173)	(78)	(60)	(69)	(68)	(77)	(90)
Balance, $m
Balance, $m	Working capital	221	74	224	112	107	122	40	46	81	78
	Total debt	8	8	212	218	172	180	50	—	—	93
	Net debt	(236)	(73)	(12)	143	72	71	(49)	(63)	(98)	(5)
	Shareholders’ equity	569	547	379	72	67	107	126	118	67	21
Returns, %
Returns, %	ROA	(19.33)	(13.03)	(65.17)	(55.01)	(44.27)	(27.33)	9.84	(52.26)	(85.20)	(285.69)
	ROIC	(23.49)	(12.67)	(62.96)	(48.56)	(38.83)	(32.17)	(61.32)	(112.05)	0.00	(425.63)
	ROE	(29.29)	(20.97)	(110.09)	(143.12)	(245.56)	(105.62)	24.24	(78.37)	(160.80)	(1,446.02)

Negative figures in brackets.

All 10 years →

Fiscal years to Dec 2025 · latest quarter Jun 2026

Charts ten years each

Company	Market cap	P/E	Fwd P/E	Revenue growth (Q)	EPS growth (Q)	FCF growth (Q)	Gross margin (Q)	EBIT margin (Q)	Compare
ELVN Enliven Therapeutics, Inc.	$2.9B	— (loss-making)	—	—	n/m	−8.34% (below 0%: shrinking)	0.00%	0.00%	Compare
DYN Dyne Therapeutics, Inc.	$2.9B	— (loss-making)	—	—	n/m	−39.08% (below 0%: shrinking)	0.00%	0.00%	Compare
NRIX Nurix Therapeutics, Inc.	$2.7B	9.7×	— (loss-making)	+8,426.27% (above 0%: growing)	n/m	+1,122.10% (above 0%: growing)	100.00%	83.12%	Compare
ZLAB Zai Lab Limited Unsponsored ADR	$2.7B	— (loss-making)	— (loss-making)	−3.33% (below 0%: shrinking)	n/m	−84.42% (below 0%: shrinking)	54.70%	(71.95%)	Compare
PGEN Precigen, Inc.	$2.6B	— (loss-making)	— (loss-making)	+6,322.66% (above 0%: growing)	n/m	+8.73% (above 0%: growing)	94.90%	41.18%
BEAM Beam Therapeutics Inc.	$2.6B	— (loss-making)	— (loss-making)	−94.21% (below 0%: shrinking)	n/m	+13.92% (above 0%: growing)	100.00%	(25,827.14%)	Compare
NAMS NewAmsterdam Pharma Company N.V.	$2.5B	— (loss-making)	— (loss-making)	−80.67% (below 0%: shrinking)	n/m	−4.07% (below 0%: shrinking)	100.00%	(1,752.61%)	Compare
MBX MBX Biosciences, Inc.	$2.4B	— (loss-making)	—	—	n/m	−29.67% (below 0%: shrinking)	—	0.00%	Compare
ADMA ADMA Biologics Inc	$2.4B	14.8×	9.5×	+1.98% (above 0%: growing)	+21.43% (above 0%: growing)	+19.72% (above 0%: growing)	69.36%	42.16%	Compare
Median of peers	$2.6B	—	—	−3.33%	—	−6.20%	69.36%	0.00%

All 614 Biotechnology stocks →

Precigen, Inc. (PGEN) key facts

Strength: Precigen, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $9.7 million, up 146.7% from fiscal 2024.
Precigen, Inc. (PGEN) is a Biotechnology company in the Healthcare sector, listed on Nasdaq.
As of October 16, 2026, PGEN traded at $6.35, a market capitalization of $2.6 billion.
Return on equity was −1,446.0% and debt-to-equity 2.15.
Its Piotroski F-score is 3 out of 9 and its Altman Z-score is −16.93 (distress zone) for fiscal 2025.

Source: company filings (standardised) and stockrow calculations.